






Claims

1. A compound represented by the following general formula (I):







wherein A represents one selected from the following formulae (Ia) to (Id):



wherein R¹ represents a hydrogen atom or a C₁-C₃ alkyl group, and R² represents a hydrogen atom or a C₁-C₃ alkyl group, or

a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 selected from the compounds represented by the following structural formulae:



; or a pharmaceutically acceptable salt

thereof.

3. A compound according to claim 1 which is 2-[6-(6,7-Dimethoxyquinolin-3-yl)pyridin-3-yl]-N-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]acetamide or a pharmaceutically acceptable salt thereof.

4. A compound according to claim 1 which is 2-[6-(6,7-Dimethoxyquinolin-3-yl)pyridin-3-yl]-N-[3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-5-yl]acetamide or a pharmaceutically acceptable salt thereof.

5. A compound according to claim 1 which is 2-[6-(6,7-Dimethoxyquinolin-3-yl)pyridin-3-yl]-N-[3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-pyrazol-5-yl]acetamide or a pharmaceutically acceptable salt thereof.

6. A compound according to claim 1 which is 2-[6-(6,7-Dimethoxyquinolin-3-yl)pyridin-3-yl]-N-[1-methyl-3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-pyrazol-5-yl]acetamide or a pharmaceutically acceptable salt thereof.
7. A compound according to any one of claims 2 to 6 as a pharmaceutically acceptable salt.
8. A compound according to claim 7 wherein the pharmaceutically acceptable salt is a methanesulfonate.
9. A RET kinase inhibitor comprising, as an active ingredient, a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof.
10. Use of the compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof for the production of a pharmaceutical composition.
11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 8 and one or more pharmaceutically acceptable excipients.
12. A compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, for use in therapy.
13. A compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of cancer.
14. A compound or a pharmaceutically acceptable salt thereof, for use according to claim 13 wherein the cancer is selected from a lung cancer, thyroid gland cancer, breast cancer and a colon cancer.
15. A compound or a pharmaceutically acceptable salt thereof, for use according to claim 13 wherein the cancer is a non-small cell lung cancer.